open access

Vol 87, No 6 (2016)
Research paper
Published online: 2016-06-30
Get Citation

Comparison of effectiveness of treatment of patients with sporadic and germline BRCA1-related ovarian cancer

Wiktor Szatkowski, Konrad Muzykiewicz, Marek Jasiówka, Kazimierz Karolewski, Zbigiew Kojs, Małgorzata Klimek, Paweł Blecharz
DOI: 10.5603/GP.2016.0019
·
Pubmed: 27418218
·
Ginekol Pol 2016;87(6):422-425.

open access

Vol 87, No 6 (2016)
ORIGINAL PAPERS Gynecology
Published online: 2016-06-30

Abstract

Objectives: Numerous reports suggest that the clinical course of ovarian cancer (OC) in BRCA, including BRCA1, mutation carriers (BRCA1-OC) is different than in patients with sporadic ovarian cancer (SOC). Most of the authors indicate more fa­vourable treatment results in patients with BRCA1-OC. The aim of the study was to compare the effectiveness of treatment of patients with advanced-stage (FIGO III/IV) SOC and BRCA1-OC.

Material and methods: Between 2004 and 2009, 957 OC patients were treated in Cracow Branch of Cancer Center, M. Sklodowska-Curie Memorial Institute, Poland. Germline BRCA1 mutation was found in 66 patients. To compare the effective­ness of treatment, the group of 47 advanced-stage BRCA1-OC patients was matched with the group of 47 advanced-stage SOC patients. Pairs of patients were matched in terms of the most important prognostic factors, i.e. stages according to FIGO, primary cytoreduction extent, tumour histologic subtype and grade, as well as year of diagnosis and treatment.

Results: The 5-year overall survival rate was 42.9% for BRCA1-OC patients and 34.3% for SOC patients (p = 0.354). Mean time to progression was 22.7 and 14.5 months for BRCA1-OC and SOC group, respectively (p = 0.05). Complete response to pri­mary surgery and first line chemotherapy was obtained in 42.5% and 37.9% of cases, respectively; the difference, however, did not reach the statistical significance.

Conclusions: Results of combined treatment in the group of BRCA1-related OC patients seem to be better than in the group of sporadic ovarian cancer patients.

Abstract

Objectives: Numerous reports suggest that the clinical course of ovarian cancer (OC) in BRCA, including BRCA1, mutation carriers (BRCA1-OC) is different than in patients with sporadic ovarian cancer (SOC). Most of the authors indicate more fa­vourable treatment results in patients with BRCA1-OC. The aim of the study was to compare the effectiveness of treatment of patients with advanced-stage (FIGO III/IV) SOC and BRCA1-OC.

Material and methods: Between 2004 and 2009, 957 OC patients were treated in Cracow Branch of Cancer Center, M. Sklodowska-Curie Memorial Institute, Poland. Germline BRCA1 mutation was found in 66 patients. To compare the effective­ness of treatment, the group of 47 advanced-stage BRCA1-OC patients was matched with the group of 47 advanced-stage SOC patients. Pairs of patients were matched in terms of the most important prognostic factors, i.e. stages according to FIGO, primary cytoreduction extent, tumour histologic subtype and grade, as well as year of diagnosis and treatment.

Results: The 5-year overall survival rate was 42.9% for BRCA1-OC patients and 34.3% for SOC patients (p = 0.354). Mean time to progression was 22.7 and 14.5 months for BRCA1-OC and SOC group, respectively (p = 0.05). Complete response to pri­mary surgery and first line chemotherapy was obtained in 42.5% and 37.9% of cases, respectively; the difference, however, did not reach the statistical significance.

Conclusions: Results of combined treatment in the group of BRCA1-related OC patients seem to be better than in the group of sporadic ovarian cancer patients.

Get Citation

Keywords

ovarian cancer, BRCA1, chemotherapy, cytoreduction

About this article
Title

Comparison of effectiveness of treatment of patients with sporadic and germline BRCA1-related ovarian cancer

Journal

Ginekologia Polska

Issue

Vol 87, No 6 (2016)

Article type

Research paper

Pages

422-425

Published online

2016-06-30

DOI

10.5603/GP.2016.0019

Pubmed

27418218

Bibliographic record

Ginekol Pol 2016;87(6):422-425.

Keywords

ovarian cancer
BRCA1
chemotherapy
cytoreduction

Authors

Wiktor Szatkowski
Konrad Muzykiewicz
Marek Jasiówka
Kazimierz Karolewski
Zbigiew Kojs
Małgorzata Klimek
Paweł Blecharz

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl